Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7554/eLife.68808 http://scihub22266oqcxt.onion/10.7554/eLife.68808 33830018!8064747!33830018     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Elife 2021 ; 10 (ä): ä Nephropedia Template TP {{tp|p=33830018|t=2021. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection |pdf=|usr=}}{{33830018}} gab.com Text Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection JO: Elife http://www.kidney.de/pget.php?&tw=1&pmid=33830018 #FOAvip The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK's first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs >/=12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease. Twit Text FOAVip Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection ????Elife http://www.kidney.de/pget.php?&tw=1&pmid=33830018 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33830018 #FOAvip English Wikipedia <ref>{{Cite pmid|33830018}}</ref> Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection #MMPMID33830018 Jones NK; Rivett L; Seaman S; Samworth RJ; Warne B; Workman C; Ferris M; Wright J; Quinnell N; Shaw A; Goodfellow IG; Lehner PJ; Howes R; Wright G; Matheson NJ; Weekes MP Elife 2021[Apr]; 10 (ä): ä PMID33830018show ga The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK's first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs >/=12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease. |Asymptomatic Infections/therapy[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/administration & dosage/*therapeutic use[MESH] |COVID-19/diagnosis/*prevention & control[MESH] |Health Personnel[MESH] |Humans[MESH] |Immunization Schedule[MESH] |Immunization, Secondary[MESH] |SARS-CoV-2/isolation & purification[MESH]Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing